Abstract:OBJECTIVE:We analyzed data of lupus nephritis (LN) patients to find parameters that can predict remission. METHODS:Sixty-four LN patients who were diagnosed with class III, IV, V or V + III/IV by renal biopsy and were followed up for more than six months in our center were enrolled retrospectively. Receiver operating characteristic curves were used to test the predictive values of urinary protein-to-creatinine ratio (UPCR), serum albumin and complement C3 at the first, second and third months as predictors for remission at the sixth month. RESULTS:The patients' renal pathologies were class III (five cases), class IV (33 cases), class V (nine cases) and class V + III/IV (17 cases). All patients received standard immunosuppressive therapy. Forty-six (71.9%) patients (grouped as the remission group) achieved remission at the end of the sixth month, including 23 complete remissions and 23 partial remissions. The other 18 patients were grouped as the no-remission group. There were no significant differences in clinical data, proportion of immunosuppressive therapy or renal pathological characteristics between the remission group and no-remission group at baseline, except the serum urea nitrogen of the remission group was lower than in the no-remission group. The UPCR were significantly lower in the remission group than in the no-remission group at months 1, 2, 3 and 6, respectively, while the serum albumin was significantly higher in the remission group than in the no-remission group at months 3 and 6, respectively. There were no significant differences in serum creatinine between the remission group and no-remission group, except at month 1. The C3 levels were higher in the remission group than in the no-remission group at months 1, 2 and 3, respectively. The areas under the curve (AUC) of the change percentage of UPCR at month 3 and the serum albumin at month 3 were the most significant (AUC 0.778, p = 0.002; AUC 0.773, p = 0.001, respectively). The cutoff value of the change percentage of UPCR at month 3 was 59%. The cutoff value of serum albumin at month 3 was 32.9g/l. CONCLUSION:The change percentage of UPCR ≥59% and the serum albumin ≥32.9 g/l at the third month were valuable for predicting remission at the sixth month in LN. Because of the small-size and retrospective nature, this study needs to be validated.

Evaluation of Renal Vascular Lesions Using Circulatory Biomarkers in Patients with Lupus Nephritis

Circulating thrombomodulin and vascular cell adhesion molecule-1 and renal vascular lesion in patients with lupus nephritis

Evaluation of renal vascular lesions using circulating endothelial cells in patients with lupus nephritis

THU0247 LRRN4: A NOVEL PROGNOSTIC BIOMARKER OF RENAL OUTCOME IN LUPUS NEPHRITIS PATIENTS

Early-stage predictors for treatment responses in patients with active lupus nephritis.

Monocyte Chemotactic Protein-1, Fractalkine, and Receptor for Advanced Glycation End Products in Different Pathological Types of Lupus Nephritis and Their Value in Different Treatment Prognoses.

Significance of Plasma and Intragiomerular Thrombomodulin in Lupus Nephritis with Vascular Lesion

Renal Microvascular Lesions in Lupus Nephritis

Renal Interstitial Arteriosclerotic Lesions In Lupus Nephritis Patients: A Cohort Study From China

The Significance of Renal Vascular Lesion in Patients with Proliferative Lupus Nephritits

Urinary levels of ceruloplasmin and monocyte chemoattractant protein-1 correlate with extra-capillary proliferation and chronic damage in patients with lupus nephritis

Influence Factors of Left Ventricular Hypertrophy in Incipient Lupus Nephritis Patients

Noninvasive biomarkers for lupus nephritis

Evaluation of vascular lesions using circulating endothelial cells in renal transplant patients.

Elevated Urinary and Blood Vascular Cell Adhesion Molecule-1 as Potential Biomarkers for Active Systemic Lupus Erythematosus: A Meta-analysis

Clinical Research of Lupus Retinopathy: Quantitative Analysis of Retinal Vessels by Optical Coherence Tomography Angiography in Patients with Systemic Lupus Erythematosus

Composite Urinary Biomarkers to Predict Pathological Tubulointerstitial Lesions in Lupus Nephritis.

Biomarkers Associated with Drugs for the Treatment of Lupus Nephritis

Inclusion of Renal Vascular Lesions in the 2003 ISN/RPS System for Classifying Lupus Nephritis Improves Renal Outcome Predictions.

Proximity extension assay proteomics and renal single cell transcriptomics uncover novel urinary biomarkers for active lupus nephritis